Rpure Life Sciences Acquires BLNH... Launches as Rpure Healthcare

[Asia Economy Reporter Chunhee Lee] Ripure Life Sciences recently announced on the 24th that it has acquired BLNH, an import and distribution company specializing in rare disease treatments and veterinary pharmaceuticals. Ripure Life Sciences will rebrand as Ripure Healthcare to mark this milestone.

Through this acquisition, Ripure Healthcare plans to solidify its research and development pipeline while strengthening its market dominance by expanding its client base and product lineup. Additionally, it has secured an industrial site of approximately 30,000㎡ within the Osong Advanced Medical Complex in Chungbuk to continuously advance its research and development (R&D) and contract development and manufacturing organization (CDMO) business model.

In particular, Ripure Healthcare aims to transform into a mid-sized pharmaceutical company with a profit-generating business model encompassing the entire value chain?from R&D and clinical trials to import, production, distribution, and export. Furthermore, the company plans to pursue a listing on the KOSDAQ market through additional corporate acquisitions.

Notably, during this acquisition process, Ripure Healthcare recruited Dr. Jaehwi Lee, a former professor at Chung-Ang University College of Pharmacy, as Chief Technology Officer (CTO) and co-CEO. Consequently, CEO Yongsang Kim will serve as co-CEO and Chief Operating Officer (COO), establishing a dual leadership management system.